HEALY JAMES — SEC insider filings

SEC reporting owner CIK 1245624. 70 insider filings on record with FilingPulse; latest filed 2026-10-30.

Transaction summary — filings shown

Covers the 50 most recent of 70 filings on record, filed 2022-04-14 to 2026-10-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Natera, Inc. (NTRA)Director20—2 legs · 646,400 sh · $37,925,49822
Rapport Therapeutics, Inc. (RAPP)Director521 legs · 1,572,336 sh · $30,938,663—4
Karuna Therapeutics, Inc. (KRTX)Director87 legs · 120,047 sh · $14,742,2391 leg · 6,027 sh · $1,204,77118
CinCor Pharma, Inc. (CINC)Director, 10% owner32 legs · 506,000 sh · $15,180,0001 leg · 6,000 sh · $85,9205
BioAge Labs, Inc. (BIOA)Director35 legs · 666,665 sh · $11,999,970—5
ArriVent Biopharma, Inc. (AVBP)Director11 leg · 444,444 sh · $7,999,992—2
Vera Therapeutics, Inc. (VERA)10% owner11 leg · 285,714 sh · $1,999,998——
Y-mAbs Therapeutics, Inc. (YMAB)Director5——18
Seaport Therapeutics, Inc. (SPTX)Director1——4
Bolt Biotherapeutics, Inc. (BOLT)Director3——3

Insider filings — HEALY JAMES

FiledFormIssuerReported transactionsSource
2026-10-304Rapport Therapeutics, Inc. (RAPP)Purchase (P): 952,380 @ $21 · Purchase (P): 6,395 @ $21 · Purchase (P): 3,772 @ $21 · Purchase (P): 6,933 @ $21EDGAR
2026-06-124BioAge Labs, Inc. (BIOA)Grant/award (A): 22,000 (derivative) @ $0EDGAR
2026-06-104Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 15,200 (derivative) @ $0EDGAR
2026-05-044Seaport Therapeutics, Inc. (SPTX)Conversion (C): 1,927,159 · Conversion (C): 804,379 · Conversion (C): 6,052,631 (derivative) @ $0 · Conversion (C): 2,526,315 (derivative) @ $0EDGAR
2025-09-184Y-mAbs Therapeutics, Inc. (YMAB)Code (U): 31,603 @ $8.60 · Disposition to issuer (D): 25,080 · Code (U): 2,194,278 @ $8.60 · Disposition to issuer (D): 14,222 (derivative) · Disposition to issuer (D): 8,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · +5 moreEDGAR
2025-07-024Y-mAbs Therapeutics, Inc. (YMAB)Grant/award (A): 25,080 @ $0 · Grant/award (A): 33,450 (derivative) @ $0EDGAR
2025-06-184Rapport Therapeutics, Inc. (RAPP)Grant/award (A): 21,850 (derivative) @ $0EDGAR
2025-06-094BioAge Labs, Inc. (BIOA)Grant/award (A): 22,000 (derivative) @ $0EDGAR
2025-04-294Natera, Inc. (NTRA)Grant/award (A): 142EDGAR
2025-02-044Natera, Inc. (NTRA)Grant/award (A): 114EDGAR
2024-10-294Natera, Inc. (NTRA)Grant/award (A): 153EDGAR
2024-09-274BioAge Labs, Inc. (BIOA)Conversion (C): 1,638,236 · Purchase (P): 588,888 @ $18 · Purchase (P): 11,113 @ $18 · Purchase (P): 18,353 @ $18 · Purchase (P): 21,814 @ $18 · Purchase (P): 26,497 @ $18 · +2 moreEDGAR
2024-07-304Natera, Inc. (NTRA)Grant/award (A): 177EDGAR
2024-07-034Rapport Therapeutics, Inc. (RAPP)Purchase (P): 3,538 @ $23.08 · Purchase (P): 3,565 @ $24.21 · Purchase (P): 4,544 @ $25.02 · Purchase (P): 2,559 @ $26.06 · Purchase (P): 3,799 @ $23.08 · Purchase (P): 3,828 @ $24.21 · +6 moreEDGAR
2024-07-024Natera, Inc. (NTRA)Grant/award (A): 2,964EDGAR
2024-06-144Bolt Biotherapeutics, Inc. (BOLT)Grant/award (A): 22,000 (derivative) @ $0EDGAR
2024-06-134Y-mAbs Therapeutics, Inc. (YMAB)Grant/award (A): 3,495 @ $0 · Grant/award (A): 14,545 (derivative) @ $0EDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)Conversion (C): 1,392,738 @ $0 · Purchase (P): 470,589 @ $17 · Purchase (P): 18,641 @ $17 · Purchase (P): 17,861 @ $17 · Purchase (P): 26,278 @ $17 · Purchase (P): 25,455 @ $17 · +1 moreEDGAR
2024-04-304Natera, Inc. (NTRA)Grant/award (A): 210EDGAR
2024-03-184Karuna Therapeutics, Inc. (KRTX)Disposition to issuer (D): 32,500 @ $330 · Disposition to issuer (D): 990 @ $330 · Disposition to issuer (D): 683 @ $330 · Disposition to issuer (D): 1,372,441 @ $330 · Disposition to issuer (D): 8,025 @ $330 · Disposition to issuer (D): 12,500 (derivative) @ $232.41 · +3 moreEDGAR
2024-01-314ArriVent Biopharma, Inc. (AVBP)Conversion (C): 1,252,308 · Purchase (P): 444,444 @ $18 · Conversion (C): 1,252,308 (derivative)EDGAR
2024-01-304Natera, Inc. (NTRA)Grant/award (A): 264 @ $63.79EDGAR
2023-12-224Natera, Inc. (NTRA)Sale (S): 644,000 @ $58.75EDGAR
2023-10-314Natera, Inc. (NTRA)Grant/award (A): 396 @ $42.60EDGAR
2023-08-014Natera, Inc. (NTRA)Grant/award (A): 328 @ $48.48EDGAR
2023-07-054Natera, Inc. (NTRA)Grant/award (A): 2,750 · Grant/award (A): 4,255 (derivative) @ $0EDGAR
2023-06-224Karuna Therapeutics, Inc. (KRTX)Grant/award (A): 990 @ $0 · Grant/award (A): 1,904 (derivative) @ $0EDGAR
2023-06-204Karuna Therapeutics, Inc. (KRTX)Other (J): 400,000 @ $0 · Other (J): 8,025 @ $0EDGAR
2023-06-144Bolt Biotherapeutics, Inc. (BOLT)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2023-06-094Y-mAbs Therapeutics, Inc. (YMAB)Grant/award (A): 2,330 @ $0 · Grant/award (A): 13,950 (derivative) @ $0EDGAR
2023-05-304Natera, Inc. (NTRA)Option exercise (M): 3,534 · Option exercise (M): 3,534 (derivative) @ $0EDGAR
2023-04-184Natera, Inc. (NTRA)Grant/award (A): 285 @ $54.73EDGAR
2023-02-274CinCor Pharma, Inc. (CINC)
jointly with Katabi Maha, Sofinnova Management X, L.P., Sofinnova Management X-A, L.L.C., Sofinnova Venture Partners X, L.P.
Sale (S): 6,000 @ $14.32 · Code (U): 9,803 · Disposition to issuer (D): 19,608 · Code (U): 6,073,949EDGAR
2023-02-084Vera Therapeutics, Inc. (VERA)
jointly with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., Katabi Maha, Sofinnova Management X-A, L.L.C.
Purchase (P): 285,714 @ $7EDGAR
2023-01-184Natera, Inc. (NTRA)Sale (S): 2,400 @ $37.71EDGAR
2023-01-184Natera, Inc. (NTRA)Grant/award (A): 390 @ $40.01EDGAR
2023-01-174Karuna Therapeutics, Inc. (KRTX)Other (J): 300,000 @ $0 · Other (J): 6,027 @ $0 · Sale (S): 6,027 @ $199.90EDGAR
2022-10-184Natera, Inc. (NTRA)Grant/award (A): 344 @ $45.42EDGAR
2022-09-024/ANatera, Inc. (NTRA)Grant/award (A): 430 @ $0EDGAR
2022-08-154CinCor Pharma, Inc. (CINC)Purchase (P): 500,000 @ $30 · Purchase (P): 6,000 @ $30EDGAR
2022-08-084CinCor Pharma, Inc. (CINC)Option exercise (M): 29,411 @ $13.60 · Option exercise (M): 29,411 (derivative) @ $0EDGAR
2022-08-084Karuna Therapeutics, Inc. (KRTX)Option exercise (M): 32,500 @ $16 · Option exercise (M): 32,500 (derivative) @ $0EDGAR
2022-07-194Y-mAbs Therapeutics, Inc. (YMAB)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2022-07-124Natera, Inc. (NTRA)Grant/award (A): 430 (derivative) @ $36.31EDGAR
2022-07-014Karuna Therapeutics, Inc. (KRTX)Purchase (P): 27,777 @ $121.99 · Purchase (P): 4,039 @ $122.95 · Purchase (P): 6,832 @ $124.73 · Purchase (P): 9,129 @ $125 · Purchase (P): 48,062 @ $122.27 · Purchase (P): 24,161 @ $123.39EDGAR
2022-06-164Karuna Therapeutics, Inc. (KRTX)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2022-06-104Bolt Biotherapeutics, Inc. (BOLT)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2022-06-014Natera, Inc. (NTRA)Grant/award (A): 3,534 (derivative) @ $0 · Grant/award (A): 7,068 (derivative) @ $0EDGAR
2022-05-274Natera, Inc. (NTRA)Option exercise (M): 1,307 · Option exercise (M): 1,307 (derivative) @ $0EDGAR
2022-04-144Karuna Therapeutics, Inc. (KRTX)Purchase (P): 47 @ $129.38EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1245624 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs